Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678470 · ClinicalTrials.gov registry record · NA
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
A NA study of Moderate to Severe Psoriasis, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00678470 is a NA study of Moderate to Severe Psoriasis that has completed, run by University of California, San Francisco. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00678470, a NA study of Moderate to Severe Psoriasis, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, open-label, pilot study. A total of 18 subjects will be enrolled in this 6 month study to evaluate whether the response to intralesional alefacept injections prior to the standard course of intramuscularly (IM) treatment can predict clinical outcomes in psoriasis patients. One lesion with a psoriasis severity assessment score greater than 3 and an induration score greater than 1 will be identified on each patient. Each lesion will receive only one intralesional alefacept injection during the first three weeks of the study (1 lesion per week). Following a 2 week observation period, subjects will undergo a standard 12 week course of weekly intramuscular alefacept injections. The Psoriasis Area Severity Index (PASI) score will be used to determine the effectiveness of the intramuscular alefacept treatments. An 8 week follow-up period will begin after the last dose of alefacept is administered where safety and efficacy measures will continue to be monitored as outlined in the study procedures. The hypothesis is that the response to intralesional alefacept injections, whether it is positive or no benefit, will predict the clinical response to intramuscular alefacept administration.
Conditions Studied
Interventions
- DRUG Intralesional Alefacept
Study Locations (1)
California
- UCSF Psoriasis and Skin Treatment Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00678470
The ClinicalTrials.gov registry entry for NCT00678470 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Intralesional Alefacept is the first listed.
NCT00678470 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00678470 about?
NCT00678470 is a clinical study titled "Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis". This is a single-center, open-label, pilot study. A total of 18 subjects will be enrolled in this 6 month study to evaluate whether the response to intralesional alefacept injections prior to the standard course of intramuscularly (IM) treatment can predict clinical outcomes in psoriasis patients. O...
What is the current status of trial NCT00678470?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2007-09. Estimated completion is 2011-06.
What conditions does trial NCT00678470 study?
This clinical trial studies the following conditions: Moderate to Severe Psoriasis.
What interventions are being tested in trial NCT00678470?
The interventions under investigation include: Intralesional Alefacept (DRUG).
Who is sponsoring clinical trial NCT00678470?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00678470 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.